Close
Novotech
Jabsco PureFlo 21 Single Use

Merck Statement Regarding FDA Approval of Changes to Trade Packaging Design

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal

Gilead Sciences has agreed to acquire Germany-based Tubulis in...

Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition

Neurocrine Biosciences is close to securing a more than...
- Advertisement -

Merck appreciates the U.S. Food and Drug Administration’s (FDA) recognition of our efforts to create new standardized product packaging for several of our medicines.

These changes to the packaging of several medicines were made by Merck as a result of comprehensive research conducted directly with pharmacists and pharmacy technicians to understand how the company could help them to further support the accuracy of medication dispensing within the pharmacy.

Michael Rosenblatt, M.D., chief medical officer for Merck said, Efforts such as this are a part of Merck’s overall commitment to help people be well. We look forward to continuing to work with regulatory agencies and healthcare professionals to implement this new design and help bring the best possible care to patients

Latest stories

Related stories

Hypercon Technology Deal Signed between Halozyme and Vertex

Halozyme Therapeutics has entered into a global exclusive partnership...

Gilead Advances ADC Pipeline Expansion with $3B Tubulis Deal

Gilead Sciences has agreed to acquire Germany-based Tubulis in...

Neurocrine Nears $2.5bn Soleno Therapeutics Acquisition

Neurocrine Biosciences is close to securing a more than...

Biogen to Acquire Apellis for $5.6 Billion in Major Deal

Biogen Inc. has agreed to acquire Apellis Pharmaceuticals Inc....

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »